AI assistant
GENETIC TECHNOLOGIES LIMITED Board/Management Information 2003
65022_rns_2003-09-01_6b447f6f-a493-4e05-9fc7-bbaf6fdc0b9e.pdf
Board/Management Information
Open in viewerOpens in your device viewer
2 September 2003
The Manager Company Announcements Office Australian Stock Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000
Dear Sir.
Professor Michael Quinn joins GTG Scientific Advisory Committee
Genetic Technologies Limited ("GTG") is pleased to announce that leading oncologist, Professor Michael A. Quinn has joined the GTG Scientific Advisory Committee.
Professor Quinn is Director of Oncology at the Royal Women's Hospital, Melbourne. He is internationally recognized as an oncologist, surgeon and medical researcher and is a medical consultant to several other hospitals in Melbourne, including the Mercy Hospital for Women, The Royal Melbourne Hospital, the Royal Children's Hospital, and the Peter MacCallum Cancer Centre. He also chairs the Board of Management of the National Cancer Control Initiative, and is an Executive Committee Member of the Cancer Council of Victoria, as well as a Board Member of the Australian Cancer Society.
Professor Ouinn has authored over 130 scientific papers, and two books, and serves on the editorial boards of many biomedical journals. He has won multiple awards and medical prizes, including the prestigious King George V Research Scholarship. His current research involves fields as diverse as basic cancer research, clinical trials of new anticancer drugs, and vaccines against cancer-causing viruses. He has made major contributions to women's community health and population health projects.
Genetic Technologies Limited . Website: www.gfg.com.au . Email: [email protected] ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy VIC 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone 61 3 9415 1135 · Fax 61 3 9417 2987 Corporate Office · Level 9, 185 Macquarie Street Sydney NSW 2000 Australia Phone 61 2 9233 5015 - Fax 61 2 9232 5313
Professor Quinn will advise GTG on a broad range of clinical medical testing issues, including the use of gene testing and gene-based therapies for cancer, particularly breast and gynecological cancers.
We are delighted to have Professor Quinn join the GTG Scientific Advisory Committee.
Yours faithfully,
Dr Mervyn Jacobson Executive Chairman